Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index
2019.05.15 Download
Hong Kong, 15 May 2019

Essex Bio-Technology Limited (“EssexBio” or the“Group” or the Company, Stock code: 1061) is pleased to announce that the Company has been included by Morgan Stanley Capital International (“MSCI”) as a constituent of the MSCI China Small Cap Index, which will be effective as of the close of 28 May 2019.

MSCI is a leading provider of global equity indexes and benchmark related products and services to investors worldwide. The MSCI China Small Cap Index is designed to measure the performance of the small cap segment of the China market. Constituent stocks included in the index are generally companies with operating base in China, demonstrating excellent performance and development prospect.
The Board of Directors believe that the inclusion of the Company into above global index proved the worldwide recognition of the Company’s track record in capital market. As MSCI is one of the most widely-used international equity benchmark by global institutional investors, more engagement by international funds is expected and should further contribute to the liquidity and market value of the Company, enhancing its corporate image and accelerating the future development of its business in the biopharmaceutical industry.
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.